State College, PA, United States
State College, PA, United States

Time filter

Source Type

News Article | April 19, 2017
Site: www.eurekalert.org

Despite broad understanding of volcanoes, our ability to predict the timing, duration, type, size, and consequences of volcanic eruptions is limited, says a new report by the National Academies of Sciences, Engineering, and Medicine WASHINGTON - Despite broad understanding of volcanoes, our ability to predict the timing, duration, type, size, and consequences of volcanic eruptions is limited, says a new report by the National Academies of Sciences, Engineering, and Medicine. To improve eruption forecasting and warnings to save lives, the report identifies research priorities for better monitoring of volcanic eruptions and three grand challenges facing the volcano science community. Volcano monitoring is critical for forecasting eruptions and mitigating risks of their hazards. However, few volcanoes are adequately observed, and many are not monitored at all. For example, fewer than half of the 169 potentially active volcanoes in the U.S. have any seismometers -- an instrument to detect small earthquakes that signal underground magma movement. And only three have continuous gas measurements, which are crucial because the composition and quantity of dissolved gases in magma drive eruptions. Enhanced monitoring combined with advances in experimental and mathematical models of volcanic processes can improve the understanding and forecasting of eruptions, the report says. The committee that conducted the study and wrote the report also highlighted the need for satellite measurements of ground deformation and gas emissions, drone observations, advanced seismic monitoring, and real-time high-speed acquisition of data during eruptions. New approaches in analytical capabilities to decipher magma history, and conceptual and experimental models of magmatic and volcanic phenomena, will provide new insights on the processes that explain how magma is generated and erupts. "There have been great improvements in conceptual models of volcanic phenomena, compared with those used a few decades ago, but the volcano science community is not yet adequately prepared for the next large eruption," said Michael Manga, professor in the department of earth and planetary science at the University of California, Berkeley, and chair of the committee. "There are fundamental challenges that need to be addressed and require a sustained effort from across disciplines. By working toward these grand challenges, the volcano science community can help quantify the global effect of eruptions and mitigate hazards, ultimately benefiting millions of people living in volcanically active areas." The committee outlined several key questions and research priorities in areas such as the processes that move and store magma beneath volcanoes; how eruptions begin, evolve, and end; how a volcano erupts; forecasting eruptions; the response of landscapes, oceans, and the atmosphere to volcanic eruptions; and the response of volcanoes to changes on Earth's surface. Based on these research priorities, the committee identified three overarching grand challenges for advancing volcano science and monitoring: Forecasting the size, duration, and hazard of eruptions by integrating observations with models Current forecasts are based on recognizing patterns in monitoring data. These approaches have had mixed success because monitoring data do not capture the diversity of volcanoes or their evolution over time. An approach based on models of physical and chemical processes, informed by monitoring data, as is done in weather forecasting, could improve the accuracy of eruption forecasts. Such an approach requires integrating data and methodologies from multiple disciplines, the report says. Quantifying the life cycles of volcanoes and overcoming our current biased understanding Current understanding of a volcano's life cycle is skewed because only a small number of volcanoes are studied. Extended monitoring from the ground, sea, and space can overcome some of these observational biases, the report says. Expanding and maintaining monitoring capabilities and supporting the infrastructure to make historical and monitoring data available are critical for advancing understanding of volcanic processes and assessing volcanic hazards. The committee noted that emerging technologies such as inexpensive sensors, drones, and new micro-analytical geochemical methods are promising tools to provide new insights into volcanic activity. Close to 100 volcanoes erupt somewhere on Earth each year. Strengthening multidisciplinary research, domestic and international research and monitoring partnerships, and training networks can help the research community maximize scientific advances that result from the study of eruptions around the world, the committee said. The report cites the ongoing eruption at Bogoslof volcano in Alaska as an example that highlights these three challenges. A remote, initially submarine volcano in the Aleutian Island arc, the eruption started in late December 2016 and the activity has been continuing as of February 2017. In just one month, the volcano produced numerous explosions with plumes rising 20,000-35,000 feet, posing a significant hazard to North Pacific aviation. The U.S. Geological Survey Alaska Volcano Observatory (AVO) has been relying on distant seismometers, satellite data, infrasound, and lightning detection to monitor the activity because there are no ground-based instruments on the volcano. The committee said AVO has been able to provide early warning for only some of these hazardous events. This eruption also underscores the limited understanding of magma eruption. In more than 20 discrete events, the emerging volcano has reshaped its coastlines repeatedly, providing snapshots of volcano-landscape interactions. The study was sponsored by the National Science Foundation, NASA, the U.S. Geological Survey, and the National Academies of Sciences, Engineering, and Medicine. The National Academies are private, nonprofit institutions that provide independent, objective analysis and advice to the nation to solve complex problems and inform public policy decisions related to science, technology, and medicine. They operate under an 1863 congressional charter to the National Academy of Sciences, signed by President Lincoln. For more information, visit http://national-academies. . A roster follows. Riya V. Anandwala, Media Relations Officer Joshua Blatt, Media Relations Assistant Office of News and Public Information 202-334-2138; e-mail news@nas.edu national-academies.org/newsroom Follow us on Twitter @theNASEM Copies of Volcanic Eruptions and Their Repose, Unrest, Precursors, and Timing are available at http://www. or by calling 202-334-3313 or 1-800-624-6242. Reporters may obtain a copy from the Office of News and Public Information (contacts listed above). THE NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE Michael Manga (chair) Professor of Earth and Planetary Science Department of Earth and Planetary Science University of California Berkeley Simon A. Carn Associate Professor Department of Geological and Mining Engineering and Sciences Michigan Technological University Houghton Katharine V. Cashman* Professor of Volcanology School of Earth Sciences University of Bristol Bristol, United Kingdom Kari M. Cooper Professor Department of Earth and Planetary Sciences University of California Davis Tobias Fischer Professor Department of Earth and Planetary Sciences University of New Mexico Albuquerque Bruce Houghton Gordon A. Macdonald Professor of Volcanology and Science Director National Disaster Preparedness Training Center School of Ocean and Earth Science and Technology University of Hawai'i Manoa Diana C. Roman Staff Scientist Department of Terrestrial Magnetism Carnegie Institution for Science Washington, D.C. Paul Segall* Professor of Geophysics School of Earth, Energy, and Environmental Sciences Stanford University Stanford, Calif.


Earth Science Tech, Inc. (OTC: ETST), an innovative biotech company focused on cannabis CBD-based (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, medical devices and its subsidiary Cannabis Therapeutics Inc. are proud to announce the achievements and updates on its CBD-based nutraceutical patent compound. Dr. Aube, Earth Science Tech's CEO and CSO, meets with Dr. Domenico and his chemical engineer every Tuesday, at Smart Medicines and have been working on three formulas. The formulas are in a solid, liquid, and semi solid form. Out of all three forms ETST's science team sees the semi solid formula's potential as a huge success. The final product looks similar to regular mustard, but it's a very special condiment that keeps all properties of full spectrum hemp oil. To read this and more news for Earth Science Tech, go to:  http://marketnewsupdates.com/news/etst.html Both the color and taste of the formula can be changed with ETST's U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST's U.S. Provisional Application No. 62/102,538, filed January 12, 2015 along with other food coloring and natural flavors. It's formulated with high industrial hemp CBD oil (30%) and CBD concentration, and can be packaged in a tube to be consumed directly as it is (half a tea spoon 3 times/day) as a nutraceutical product. The product can keep the same texture and inert ingredients as the nutraceutical product but, with modulations of the amount of hemp oil (between 5% and 30%), and can be sold as a functional food, a condiment to flavor everyday food, as well as a dietary supplement. Nickolas S. Tabraue ETST's President and COO updates the market, "We are still on track to release our highly anticipated, world-first High Grade Hemp CBD Strawberry Orange Blossom, Pet CBD, and our new edible line in mid-May as mentioned on April 20, 2017. Bottling and packaging look to commence during the first week of May and we plan on showing images on our new products and packaging very soon. Our Chief Sales Officer, Gabriel Aviles, has been receiving endless pre-order requests on our new line and we are on pace to have a record breaking month. Aside from our new products, packaging, and positive revenue forecast, we are looking to finalize a few major breakthroughs I will be excited to share when we have something more concrete in place. We greatly appreciate our loyal stakeholders' support and look forward on showing the public where all the support has taken us, and what it has helped us build." In other Industry news and developments: Cannabis Sativa, Inc. (OTCQB: CBDS) closed up over 15% on Monday at $5.8908 by the market close.  Cannabis Sativa. Inc. announced in late April that the Company has developed a "hi" branded infused honey product (hi honey) which is made from rich African honey and infused with CBD or THC. CBDS President David Tobias said that, "the hi honey flavor is rich, dark and unique." Mr. Tobias went on to express his belief that, "superfood honey contains powerful compounds including probiotics and polyphenols, which could help fight inflammation and protect cells from damage." Vitality Biopharma, Inc. (OTCQB: VBIO) closed up also on Monday at $2.35 by the market close. Vitality Biopharma, a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, on 4/20 announced the release of one of the first clinical reports detailing the ability of cannabinoid therapy to induce remission in a pediatric inflammatory bowel disease patient. Terra Tech Corp. (OTCQX: TRTC), a vertically integrated cannabis-focused agriculture company, late last week announced that its Chairman and Chief Executive Officer, Derek Peterson, will present at the 2017 Canaccord Genuity Cannabis Conference on Wednesday, May 10th at 1:00 PM Eastern at The Intercontinental Barclay New York in New York City. Derek Peterson, Chairman and CEO of Terra Tech Corp., commented, "Canaccord is one of the leading investment banks with expertise in the cannabis sector and we are pleased to be invited to present at its conference. Terra Tech continues to go from strength to strength and we look forward to educating interested investors about our business." mCig, Inc. (OTCQB: MCIG) a leading distributor of innovative products, technologies and services for the global medical cannabis industry is pleased to announce yesterday the launch of 420 Cloud on Google Play (and available soon in the Apple store), the company's latest addition to its technology division. 420 Cloud is an app-based unified community platform, sort of, 'LinkedIn meets Tinder of cannabis', and intuitively connects like-minded individuals whether they are patients, doctors, growers, dispensaries, investors, businesses, entrepreneurs, or recreational users through targeted filters, interests, jobs, news and more. mCig will promote its app through various channels totaling a reach of over one billion. DISCLAIMER:  MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated three thousand nine hundred dollars for news coverage of the current press release issued by Earth Science Tech, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.


Hollywood, April 11, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC:ETST OTCBB:ETST $ETST OTC PINK:ETST) ("ETST" or "the Company"), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, and its two subsidiaries Earth Science Pharmaceutical Inc. and Cannabis Therapeutics Inc., are proud to announce that they will be targeting breast cancer and other women’s health issues with their latest cannabis CBD-based (Indutrial Hemp) pharmaceutical drug development and research initiatives. At the monthly Scientific Advisory Board development meeting on April 4th, attended by Dr. Chandra Panchal, Dr. Domenico Fuoco, Dr. Moutih Rafei, CEO/CSO Dr. Michel Aubé, and representatives of Smart Medicine, Inc., the group decided that their drug development initiative should target breast cancer and other women’s health issues. Cannabis-based treatments have proven to be tremendously effective in treating various forms of cancer, including breast cancer, and Dr. Michel Aubé has years of expertise in this specific niche. With the new direction established, the company has re-focused on several initiatives that will benefit the health of women worldwide. Around the world, women suffer from lack of access to healthcare, both for economic and political reasons, and an inability to take charge of their own health and healthcare. ETST is committed to developing products and services that give women easier access and more control over specific health issues that impact their lives. The company is launching an in-depth study of cannabidiol’s known, unique anti-proliferative effect on breast cancer cells. CEO and Chief Scientific Officer Dr. Michel Aubé will leverage his expertise in this subject, having conducted research on deciphering the mechanism of action of organochlorine on breast cancer cells in his doctorate studies, to lead the group through the drug development pipeline. His previous work resulted in this scientific paper regarding breast cancer: https://www.ncbi.nlm.nih.gov/pubmed/18275596 ETST’s goal is to bring generic pharmaceutical breast cancer and chemo-prevention drugs to market, making them affordable and available to women around the globe. Several of the company’s immediate drug development projects will target breast and ovarian cancers, allowing that important work to benefit from an established in vitro and in vivo experimental infrastructure. Dr. Moutih and Dr. Aube will plan all in vitro and in vivo experiments and Dr. Rafei’s will supervise all experimental procedures. The company’s relationships with Dr. Rafei’s and Smart Medicine will allow it to apply for public and private research grants to engage in R&D to: Additionally, ETST is working on building a strategic partnership with Connexions Commerciales Internationales C.T. Inc., a company focused on hormonal replacement therapies. As previously announced, https://globenewswire.com/news-release/2017/03/27/945536/0/en/Earth-Science-Tech-Inc-Announces-Timeline-Projection-for-its-MSN-2-Medical-Device-and-Partnership-Negotiations-for-its-Cannabis-CBD-Based-Generic-Drugs-Medical-Device-Distribution.html. Many of their generic drugs will also be targeted to women health issues. ETST’s other subsidiary, Earth Science Pharmaceutical Inc., is launching its first product, a medical device that will empower women to take an active role to protect themselves from the long-term medical problems caused by the Sexually Transmitted Infections chlamydia and gonorrhea.  ETST continuously plans on updating its shareholders on the above mentioned studies as further progress and development occurs. About Earth Science Tech, Inc. (ETST): Earth Science Tech is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, Phytoceuticals, Pharmaceuticals, and Medical devises for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. Visit corporate website at www.earthsciencetech.com ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products. Some of ETST accomplishments and reports on its High-Grade CBD Hemp Oil include: About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com The accuracy of the MSN-2 medical device for the diagnosis of women with Chlamydia has already been proven via a study of 510 female patients, which showed PCR testing results on paired samples to be identical for 493 (96.6%) of the 510 women. To view this study, visit Evaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women. About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com  Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The 3 cannabis cannabinoid-based nutraceutcial patents and 2 generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015. FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products. SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.


Hollywood, April 20, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST), an innovative biotech company focused on cannabis (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, medical devices, and its two subsidiaries Earth Science Pharmaceutical Inc. and Cannabis Therapeutics Inc. are proud to announce the completion and launch of their informative Cannabis Therapeutics website, and in addition to providing updates on the development of the cannabinoid-based Patent nutraceutical products. We have successfully launched the website, http://cannabisthera.com, and will continue to update with new content regularly, in order to show transparency, provide the most up-to-date product information and keep investors informed. This will include a corporate blog with more frequent updates on the company’s work and monthly videos with Dr. Aube and his team. Over the past several weeks, executives from Earth Science Tech have been meeting with the R&D team from Smart Medicine. In the last weekly meeting, several milestones were discussed and progress has been made. Formulations for the company’s three varieties of High Grade Industrial Hemp CBD Oil nutraceutical formulas have been completed. The company is moving forward quickly on its International Application for Provisional Patents, and this progress was discussed. Formulations leveraging ETST’s U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST’s U.S. Provisional Application No. 62/102,538, filed January 12, 2015 to oxidative stress for athletes, individuals with chronic inflammation, and women during peri-menopause and menopause are being actively developed as part of the new Women’s Health initiatives the company recently announced, (https://globenewswire.com/news-release/2017/04/11/958716/0/en/Earth-Science-Tech-Inc-Targets-Breast-Cancer-and-Other-Women-s-Health-Issues-in-New-Cannabis-CBD-Based-Pharmaceutical-Drug-Development-Initiatives.html). The resulting formulas are expected to be beneficial for Parkinson’s, Alzheimer, and cancer patients as well. The first formula is expected to be finished and ready for testing in mid 2017. “The applications of nutraceuticals that leverage ETST’s U.S. Provisional Application N. 62/061,577 and ETST’s U.S. Provisional Application No. 62/102,538 to prevent oxidative stress are near endless,” said CEO & CSO Dr. Michel Aube, “We see a tremendous market that goes far beyond the initial scope we were pursuing, and things are moving very quickly. We are quite optimistic with the results we have seen thus far.” The company is expecting to have its High Grade Industrial Hemp CBD Patent pending formulas ready to be sold in stores by the end of 2017. “After speaking with Michel and hearing the optimism coming from the development work being completed, we’re expanding our horizons,” said CSO Gabriel Aviles, “We are expecting to be able to reach a great deal of new customers with our niche provisional patent products. Q3 and Q4 will be huge for us in terms of gaining a foothold on these markets.” “In addition to all of the hard work our scientific teams are doing, we are still on track to launch our Pet CBD products and revamped packaging we mentioned in March (https://globenewswire.com/news-release/2017/03/30/947031/0/en/Earth-Science-Tech-Inc-Expands-Marketing-Campaign-to-MassRoots-OTC-MSRT-Natural-Awakenings-Magazine-and-Enhances-Product-Packaging.html), as well a new flavored High Grade Hemp CBD Oil with added therapeutic properties (new to the market) and therapeutic edibles as early as this May. We plan on sharing these new exciting innovative products as we get closer to launching. Our team has been working hard on making sure to be the forefront in the CBD industry and making sure we can continue helping and positively changing individual’s lives.” concluded President & COO Nickolas Tabraue. ETST continuously plans on updating its shareholders on the above mentioned studies and new products as further progress and development occurs. About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. To find out more information on all our research please visit our website: www.earthsciencetech.com ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products. Some of ETST accomplishments and reports on its High-Grade CBD Hemp Oil include: • Earth Science Tech Announces the Conclusion of Phase 1 Trial with Former Professional Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/12/09/794223/0/en/Earth-Science-Tech-Announces-the-Conclusion-of-Phase-1-Trial-with-Former-Professional-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html) • Earth Science Tech Starts 30-day Trial Study with Former Professional Football Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/10/29/781678/0/en/Earth-Science-Tech-Starts-30-day-Trial-Study-with-Former-Professional-Football-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html) • Earth Science Tech Files International PCT on its Hemp CBD (Cannabidiol) Invention and Provisional Patent “Cannabidiol Compositions Including Mixtures and Uses Thereof” Related to Treating Cancer, Modulation of the Immune System and Neuroprotection. (https://globenewswire.com/news-release/2015/10/20/777795/0/en/Earth-Science-Tech-Files-International-PCT-on-its-Hemp-CBD-Cannabidiol-Invention-and-Provisional-Patent-Cannabidiol-Compositions-Including-Mixtures-and-Uses-Thereof-Related-to-Trea.html) • Earth Science Tech Announces Case Studies to Begin With Former Pro Athletes. ETST announces the start of trial studies with former professional football players using the ETST High Grade Hemp Cannabidiol (CBD). (https://globenewswire.com/news-release/2015/10/16/776942/0/en/Earth-Science-Tech-Announces-Case-Studies-to-Begin-With-Former-Pro-Athletes.html) • DV Biologics Reports: Earth Science Tech (ETST) Hemp CBD (Cannabidiol) Oil Deters the Formation of Reactive Oxygen Species (ROS) on Human Brain Cells: May serve as a Neuroprotectant. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm) • DV Biologics, a Leading Biological Company, Reports Earth Science Tech (ETST) High Grade Hemp CBD (Cannabidiol) Oil Reduces Oxidative Stress and Lipid Peroxidation on Human Brain Cells In Vitro. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm) • Earth Science Tech Announces Positive Test Results of Its Product CBD (Cannabidiol) Rich Hemp Oil; In Collaboration with the University of Central Oklahoma, Test Results Demonstrate That CBD Rich Hemp Oil Enhances Immune Function. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-test-results-its-product-cbd-cannabidiol-rich-otcqb-etst-1985844.htm) • Earth Science Tech Secures Ground Breaking Second Provisional Patent for Its CBD(Cannabidiol) Rich Hemp Oil Because of Its Findings with the University of Central Oklahoma and the Effects of CBD on Immune Cells. (http://www.marketwired.com/press-release/earth-science-tech-secures-ground-breaking-second-provisional-patent-its-cbd-cannabidiol-otcqb-etst-1983756.htm)  • Earth Science Tech Announces Positive Preliminary Test Results on the Effects of Its Hemp Oil Enriched With CBD-Cannabidiol on Animal Breast Cancer Cells and on Normal Cells. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-preliminary-test-results-on-effects-its-hemp-oil-otcqb-etst-1956064.htm) • ETST and College of Mathematics and Science at the University of Central Oklahoma Join Forces in a Joint Effort to Study the Biological and Anti-Tumor Effects of ETST All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil on Cancer Cells. (http://www.marketwired.com/press-release/etst-college-mathematics-science-university-central-oklahoma-join-forces-joint-effort-otcqb-etst-1949268.htm) About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com The accuracy of the MSN-2 medical device for the diagnosis of women with Chlamydia has already been proven via a study of 510 female patients, which showed PCR testing results on paired samples to be identical for 493 (96.6%) of the 510 women. To view this study, visit Evaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women. About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com  Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The 3 cannabis cannabinoid-based nutraceutcial patents and 2 generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015. FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products. SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.


Hollywood, April 20, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST), an innovative biotech company focused on cannabis (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, medical devices, and its two subsidiaries Earth Science Pharmaceutical Inc. and Cannabis Therapeutics Inc. are proud to announce the completion and launch of their informative Cannabis Therapeutics website, and in addition to providing updates on the development of the cannabinoid-based Patent nutraceutical products. We have successfully launched the website, http://cannabisthera.com, and will continue to update with new content regularly, in order to show transparency, provide the most up-to-date product information and keep investors informed. This will include a corporate blog with more frequent updates on the company’s work and monthly videos with Dr. Aube and his team. Over the past several weeks, executives from Earth Science Tech have been meeting with the R&D team from Smart Medicine. In the last weekly meeting, several milestones were discussed and progress has been made. Formulations for the company’s three varieties of High Grade Industrial Hemp CBD Oil nutraceutical formulas have been completed. The company is moving forward quickly on its International Application for Provisional Patents, and this progress was discussed. Formulations leveraging ETST’s U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST’s U.S. Provisional Application No. 62/102,538, filed January 12, 2015 to oxidative stress for athletes, individuals with chronic inflammation, and women during peri-menopause and menopause are being actively developed as part of the new Women’s Health initiatives the company recently announced, (https://globenewswire.com/news-release/2017/04/11/958716/0/en/Earth-Science-Tech-Inc-Targets-Breast-Cancer-and-Other-Women-s-Health-Issues-in-New-Cannabis-CBD-Based-Pharmaceutical-Drug-Development-Initiatives.html). The resulting formulas are expected to be beneficial for Parkinson’s, Alzheimer, and cancer patients as well. The first formula is expected to be finished and ready for testing in mid 2017. “The applications of nutraceuticals that leverage ETST’s U.S. Provisional Application N. 62/061,577 and ETST’s U.S. Provisional Application No. 62/102,538 to prevent oxidative stress are near endless,” said CEO & CSO Dr. Michel Aube, “We see a tremendous market that goes far beyond the initial scope we were pursuing, and things are moving very quickly. We are quite optimistic with the results we have seen thus far.” The company is expecting to have its High Grade Industrial Hemp CBD Patent pending formulas ready to be sold in stores by the end of 2017. “After speaking with Michel and hearing the optimism coming from the development work being completed, we’re expanding our horizons,” said CSO Gabriel Aviles, “We are expecting to be able to reach a great deal of new customers with our niche provisional patent products. Q3 and Q4 will be huge for us in terms of gaining a foothold on these markets.” “In addition to all of the hard work our scientific teams are doing, we are still on track to launch our Pet CBD products and revamped packaging we mentioned in March (https://globenewswire.com/news-release/2017/03/30/947031/0/en/Earth-Science-Tech-Inc-Expands-Marketing-Campaign-to-MassRoots-OTC-MSRT-Natural-Awakenings-Magazine-and-Enhances-Product-Packaging.html), as well a new flavored High Grade Hemp CBD Oil with added therapeutic properties (new to the market) and therapeutic edibles as early as this May. We plan on sharing these new exciting innovative products as we get closer to launching. Our team has been working hard on making sure to be the forefront in the CBD industry and making sure we can continue helping and positively changing individual’s lives.” concluded President & COO Nickolas Tabraue. ETST continuously plans on updating its shareholders on the above mentioned studies and new products as further progress and development occurs. About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. To find out more information on all our research please visit our website: www.earthsciencetech.com ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products. Some of ETST accomplishments and reports on its High-Grade CBD Hemp Oil include: • Earth Science Tech Announces the Conclusion of Phase 1 Trial with Former Professional Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/12/09/794223/0/en/Earth-Science-Tech-Announces-the-Conclusion-of-Phase-1-Trial-with-Former-Professional-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html) • Earth Science Tech Starts 30-day Trial Study with Former Professional Football Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/10/29/781678/0/en/Earth-Science-Tech-Starts-30-day-Trial-Study-with-Former-Professional-Football-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html) • Earth Science Tech Files International PCT on its Hemp CBD (Cannabidiol) Invention and Provisional Patent “Cannabidiol Compositions Including Mixtures and Uses Thereof” Related to Treating Cancer, Modulation of the Immune System and Neuroprotection. (https://globenewswire.com/news-release/2015/10/20/777795/0/en/Earth-Science-Tech-Files-International-PCT-on-its-Hemp-CBD-Cannabidiol-Invention-and-Provisional-Patent-Cannabidiol-Compositions-Including-Mixtures-and-Uses-Thereof-Related-to-Trea.html) • Earth Science Tech Announces Case Studies to Begin With Former Pro Athletes. ETST announces the start of trial studies with former professional football players using the ETST High Grade Hemp Cannabidiol (CBD). (https://globenewswire.com/news-release/2015/10/16/776942/0/en/Earth-Science-Tech-Announces-Case-Studies-to-Begin-With-Former-Pro-Athletes.html) • DV Biologics Reports: Earth Science Tech (ETST) Hemp CBD (Cannabidiol) Oil Deters the Formation of Reactive Oxygen Species (ROS) on Human Brain Cells: May serve as a Neuroprotectant. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm) • DV Biologics, a Leading Biological Company, Reports Earth Science Tech (ETST) High Grade Hemp CBD (Cannabidiol) Oil Reduces Oxidative Stress and Lipid Peroxidation on Human Brain Cells In Vitro. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm) • Earth Science Tech Announces Positive Test Results of Its Product CBD (Cannabidiol) Rich Hemp Oil; In Collaboration with the University of Central Oklahoma, Test Results Demonstrate That CBD Rich Hemp Oil Enhances Immune Function. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-test-results-its-product-cbd-cannabidiol-rich-otcqb-etst-1985844.htm) • Earth Science Tech Secures Ground Breaking Second Provisional Patent for Its CBD(Cannabidiol) Rich Hemp Oil Because of Its Findings with the University of Central Oklahoma and the Effects of CBD on Immune Cells. (http://www.marketwired.com/press-release/earth-science-tech-secures-ground-breaking-second-provisional-patent-its-cbd-cannabidiol-otcqb-etst-1983756.htm)  • Earth Science Tech Announces Positive Preliminary Test Results on the Effects of Its Hemp Oil Enriched With CBD-Cannabidiol on Animal Breast Cancer Cells and on Normal Cells. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-preliminary-test-results-on-effects-its-hemp-oil-otcqb-etst-1956064.htm) • ETST and College of Mathematics and Science at the University of Central Oklahoma Join Forces in a Joint Effort to Study the Biological and Anti-Tumor Effects of ETST All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil on Cancer Cells. (http://www.marketwired.com/press-release/etst-college-mathematics-science-university-central-oklahoma-join-forces-joint-effort-otcqb-etst-1949268.htm) About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com The accuracy of the MSN-2 medical device for the diagnosis of women with Chlamydia has already been proven via a study of 510 female patients, which showed PCR testing results on paired samples to be identical for 493 (96.6%) of the 510 women. To view this study, visit Evaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women. About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com  Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The 3 cannabis cannabinoid-based nutraceutcial patents and 2 generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015. FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products. SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.


Hollywood, April 20, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST), an innovative biotech company focused on cannabis (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, medical devices, and its two subsidiaries Earth Science Pharmaceutical Inc. and Cannabis Therapeutics Inc. are proud to announce the completion and launch of their informative Cannabis Therapeutics website, and in addition to providing updates on the development of the cannabinoid-based Patent nutraceutical products. We have successfully launched the website, http://cannabisthera.com, and will continue to update with new content regularly, in order to show transparency, provide the most up-to-date product information and keep investors informed. This will include a corporate blog with more frequent updates on the company’s work and monthly videos with Dr. Aube and his team. Over the past several weeks, executives from Earth Science Tech have been meeting with the R&D team from Smart Medicine. In the last weekly meeting, several milestones were discussed and progress has been made. Formulations for the company’s three varieties of High Grade Industrial Hemp CBD Oil nutraceutical formulas have been completed. The company is moving forward quickly on its International Application for Provisional Patents, and this progress was discussed. Formulations leveraging ETST’s U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST’s U.S. Provisional Application No. 62/102,538, filed January 12, 2015 to oxidative stress for athletes, individuals with chronic inflammation, and women during peri-menopause and menopause are being actively developed as part of the new Women’s Health initiatives the company recently announced, (https://globenewswire.com/news-release/2017/04/11/958716/0/en/Earth-Science-Tech-Inc-Targets-Breast-Cancer-and-Other-Women-s-Health-Issues-in-New-Cannabis-CBD-Based-Pharmaceutical-Drug-Development-Initiatives.html). The resulting formulas are expected to be beneficial for Parkinson’s, Alzheimer, and cancer patients as well. The first formula is expected to be finished and ready for testing in mid 2017. “The applications of nutraceuticals that leverage ETST’s U.S. Provisional Application N. 62/061,577 and ETST’s U.S. Provisional Application No. 62/102,538 to prevent oxidative stress are near endless,” said CEO & CSO Dr. Michel Aube, “We see a tremendous market that goes far beyond the initial scope we were pursuing, and things are moving very quickly. We are quite optimistic with the results we have seen thus far.” The company is expecting to have its High Grade Industrial Hemp CBD Patent pending formulas ready to be sold in stores by the end of 2017. “After speaking with Michel and hearing the optimism coming from the development work being completed, we’re expanding our horizons,” said CSO Gabriel Aviles, “We are expecting to be able to reach a great deal of new customers with our niche provisional patent products. Q3 and Q4 will be huge for us in terms of gaining a foothold on these markets.” “In addition to all of the hard work our scientific teams are doing, we are still on track to launch our Pet CBD products and revamped packaging we mentioned in March (https://globenewswire.com/news-release/2017/03/30/947031/0/en/Earth-Science-Tech-Inc-Expands-Marketing-Campaign-to-MassRoots-OTC-MSRT-Natural-Awakenings-Magazine-and-Enhances-Product-Packaging.html), as well a new flavored High Grade Hemp CBD Oil with added therapeutic properties (new to the market) and therapeutic edibles as early as this May. We plan on sharing these new exciting innovative products as we get closer to launching. Our team has been working hard on making sure to be the forefront in the CBD industry and making sure we can continue helping and positively changing individual’s lives.” concluded President & COO Nickolas Tabraue. ETST continuously plans on updating its shareholders on the above mentioned studies and new products as further progress and development occurs. About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. To find out more information on all our research please visit our website: www.earthsciencetech.com ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products. Some of ETST accomplishments and reports on its High-Grade CBD Hemp Oil include: • Earth Science Tech Announces the Conclusion of Phase 1 Trial with Former Professional Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/12/09/794223/0/en/Earth-Science-Tech-Announces-the-Conclusion-of-Phase-1-Trial-with-Former-Professional-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html) • Earth Science Tech Starts 30-day Trial Study with Former Professional Football Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/10/29/781678/0/en/Earth-Science-Tech-Starts-30-day-Trial-Study-with-Former-Professional-Football-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html) • Earth Science Tech Files International PCT on its Hemp CBD (Cannabidiol) Invention and Provisional Patent “Cannabidiol Compositions Including Mixtures and Uses Thereof” Related to Treating Cancer, Modulation of the Immune System and Neuroprotection. (https://globenewswire.com/news-release/2015/10/20/777795/0/en/Earth-Science-Tech-Files-International-PCT-on-its-Hemp-CBD-Cannabidiol-Invention-and-Provisional-Patent-Cannabidiol-Compositions-Including-Mixtures-and-Uses-Thereof-Related-to-Trea.html) • Earth Science Tech Announces Case Studies to Begin With Former Pro Athletes. ETST announces the start of trial studies with former professional football players using the ETST High Grade Hemp Cannabidiol (CBD). (https://globenewswire.com/news-release/2015/10/16/776942/0/en/Earth-Science-Tech-Announces-Case-Studies-to-Begin-With-Former-Pro-Athletes.html) • DV Biologics Reports: Earth Science Tech (ETST) Hemp CBD (Cannabidiol) Oil Deters the Formation of Reactive Oxygen Species (ROS) on Human Brain Cells: May serve as a Neuroprotectant. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm) • DV Biologics, a Leading Biological Company, Reports Earth Science Tech (ETST) High Grade Hemp CBD (Cannabidiol) Oil Reduces Oxidative Stress and Lipid Peroxidation on Human Brain Cells In Vitro. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm) • Earth Science Tech Announces Positive Test Results of Its Product CBD (Cannabidiol) Rich Hemp Oil; In Collaboration with the University of Central Oklahoma, Test Results Demonstrate That CBD Rich Hemp Oil Enhances Immune Function. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-test-results-its-product-cbd-cannabidiol-rich-otcqb-etst-1985844.htm) • Earth Science Tech Secures Ground Breaking Second Provisional Patent for Its CBD(Cannabidiol) Rich Hemp Oil Because of Its Findings with the University of Central Oklahoma and the Effects of CBD on Immune Cells. (http://www.marketwired.com/press-release/earth-science-tech-secures-ground-breaking-second-provisional-patent-its-cbd-cannabidiol-otcqb-etst-1983756.htm)  • Earth Science Tech Announces Positive Preliminary Test Results on the Effects of Its Hemp Oil Enriched With CBD-Cannabidiol on Animal Breast Cancer Cells and on Normal Cells. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-preliminary-test-results-on-effects-its-hemp-oil-otcqb-etst-1956064.htm) • ETST and College of Mathematics and Science at the University of Central Oklahoma Join Forces in a Joint Effort to Study the Biological and Anti-Tumor Effects of ETST All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil on Cancer Cells. (http://www.marketwired.com/press-release/etst-college-mathematics-science-university-central-oklahoma-join-forces-joint-effort-otcqb-etst-1949268.htm) About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com The accuracy of the MSN-2 medical device for the diagnosis of women with Chlamydia has already been proven via a study of 510 female patients, which showed PCR testing results on paired samples to be identical for 493 (96.6%) of the 510 women. To view this study, visit Evaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women. About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com  Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The 3 cannabis cannabinoid-based nutraceutcial patents and 2 generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015. FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products. SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.


Hollywood, May 02, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST), an innovative biotech company focused on cannabis CBD-based (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, medical devices and it’s subsidiary Cannabis Therapeutics Inc. are proud to announce the achievements and updates on its CBD-based nutraceutical patent compound. Dr. Aube Earth Science Tech’s CEO & CSO, meets with Dr. Domenico and his chemical engineer every Tuesday, at Smart Medicines and have been working on three formulas. The formulas are in a solid, liquid, and semi solid form. Out of all three forms ETST’s science team sees the semi solid formula’s potential as a huge success. The final product looks similar to regular mustard, but it’s a very special condiment that keeps all properties of full spectrum hemp oil. Both the color and taste of the formula can be changed with ETST’s U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST’s U.S. Provisional Application No. 62/102,538, filed January 12, 2015 along with other food coloring and natural flavors. It’s formulated with high industrial hemp CBD oil (30%) and CBD concentration, and can be packaged in a tube to be consumed directly as it is (half a tea spoon 3 times/day) as a nutraceutical product. The product can keep the same texture and inert ingredients as the nutraceutical product but, with modulations of the amount of hemp oil (between 5% and 30%), and can be sold as a functional food, a condiment to flavor everyday food, as well as a dietary supplement. For distinction between functional foods, nutraceuticals, and dietary supplements you can read this paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750935/ Text from the paper: “Thus, nutraceuticals (as per the proposed definition) differ from dietary supplements in the following aspects: Nutraceuticals must not only supplement the diet but should also aid in the prevention and/or treatment of disease and/or disorder. CONCLUSION When a functional food aids in the prevention and/or treatment of disease(s) and/or disorder(s) (except anemia), it is called a nutraceutical. The proposed definition can help form distinction between functional foods, nutraceuticals, and dietary supplements. ” There is no rule for the nutraceutical products. We can claim that our product is a nutraceutical and ongoing research. In conclusion, we have the first nutraceutical formula with ETST’s U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST’s U.S. Provisional Application No. 62/102,538, filed January 12, 2015 nearly ready to apply to get a natural product number (NPN is mandatory to get license to sale in Canada) and FDA approval (Federal Food, Drug, and Cosmetic Act). Dr. Aube stated, “I’m very proud and happy with our Science team achieving such great formulas and reaching closer to finalizing our three planned compounds. We look to be on track from our March 6, 2017 announcement and look forward on sharing more updates as we continue progressing. We plan on sharing our first video on our Cannabis Therapeutics along with many photos to share with our investors our profession very soon as well as finalizing Earth Science Pharmaceutical website that looks to be finalized within May.” Nickolas S. Tabraue ETST’s President & COO updates the market, “We are still on track to release our highly anticipated, world-first High Grade Hemp CBD Strawberry Orange Blossom, Pet CBD, and our new edible line in mid-May as mentioned on April 20, 2017. Bottling and packaging look to commence during the first week of May and we plan on showing images on our new products and packaging very soon. Our Chief Sales Officer, Gabriel Aviles, has been receiving endless pre-order requests on our new line and we are on pace to have a record breaking month. Aside from our new products, packaging, and positive revenue forecast, we are looking to finalize a few major breakthroughs I will be excited to share when we have something more concrete in place. We greatly appreciate our loyal stakeholders’ support and look forward on showing the public where all the support has taken us, and what it has helped us build.” ETST continuously plans on updating its shareholders on the above mentioned studies and new products as further progress and development occurs. About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. To find out more information on all our research please visit our website: www.earthsciencetech.com ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products. Some of ETST accomplishments and reports on its High-Grade CBD Hemp Oil include: • Earth Science Tech Announces the Conclusion of Phase 1 Trial with Former Professional Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/12/09/794223/0/en/Earth-Science-Tech-Announces-the-Conclusion-of-Phase-1-Trial-with-Former-Professional-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html) • Earth Science Tech Starts 30-day Trial Study with Former Professional Football Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/10/29/781678/0/en/Earth-Science-Tech-Starts-30-day-Trial-Study-with-Former-Professional-Football-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html) • Earth Science Tech Files International PCT on its Hemp CBD (Cannabidiol) Invention and Provisional Patent “Cannabidiol Compositions Including Mixtures and Uses Thereof” Related to Treating Cancer, Modulation of the Immune System and Neuroprotection. (https://globenewswire.com/news-release/2015/10/20/777795/0/en/Earth-Science-Tech-Files-International-PCT-on-its-Hemp-CBD-Cannabidiol-Invention-and-Provisional-Patent-Cannabidiol-Compositions-Including-Mixtures-and-Uses-Thereof-Related-to-Trea.html) • Earth Science Tech Announces Case Studies to Begin With Former Pro Athletes. ETST announces the start of trial studies with former professional football players using the ETST High Grade Hemp Cannabidiol (CBD). (https://globenewswire.com/news-release/2015/10/16/776942/0/en/Earth-Science-Tech-Announces-Case-Studies-to-Begin-With-Former-Pro-Athletes.html) • DV Biologics Reports: Earth Science Tech (ETST) Hemp CBD (Cannabidiol) Oil Deters the Formation of Reactive Oxygen Species (ROS) on Human Brain Cells: May serve as a Neuroprotectant. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm) • DV Biologics, a Leading Biological Company, Reports Earth Science Tech (ETST) High Grade Hemp CBD (Cannabidiol) Oil Reduces Oxidative Stress and Lipid Peroxidation on Human Brain Cells In Vitro. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm) • Earth Science Tech Announces Positive Test Results of Its Product CBD (Cannabidiol) Rich Hemp Oil; In Collaboration with the University of Central Oklahoma, Test Results Demonstrate That CBD Rich Hemp Oil Enhances Immune Function. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-test-results-its-product-cbd-cannabidiol-rich-otcqb-etst-1985844.htm) • Earth Science Tech Secures Ground Breaking Second Provisional Patent for Its CBD(Cannabidiol) Rich Hemp Oil Because of Its Findings with the University of Central Oklahoma and the Effects of CBD on Immune Cells. (http://www.marketwired.com/press-release/earth-science-tech-secures-ground-breaking-second-provisional-patent-its-cbd-cannabidiol-otcqb-etst-1983756.htm)  • Earth Science Tech Announces Positive Preliminary Test Results on the Effects of Its Hemp Oil Enriched With CBD-Cannabidiol on Animal Breast Cancer Cells and on Normal Cells. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-preliminary-test-results-on-effects-its-hemp-oil-otcqb-etst-1956064.htm) • ETST and College of Mathematics and Science at the University of Central Oklahoma Join Forces in a Joint Effort to Study the Biological and Anti-Tumor Effects of ETST All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil on Cancer Cells. (http://www.marketwired.com/press-release/etst-college-mathematics-science-university-central-oklahoma-join-forces-joint-effort-otcqb-etst-1949268.htm) About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com The accuracy of the MSN-2 medical device for the diagnosis of women with Chlamydia has already been proven via a study of 510 female patients, which showed PCR testing results on paired samples to be identical for 493 (96.6%) of the 510 women. To view this study, visit Evaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women. About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com  Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The 3 cannabis cannabinoid-based nutraceutcial patents and 2 generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015. FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products. SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Loading Earth Science collaborators
Loading Earth Science collaborators